Suppr超能文献

甲氨蝶呤与骨髓中期相。

Methotrexate and bone marrow metaphases.

作者信息

Cunningham J J, Potter A M, Watmore A E, Winfield D A

机构信息

Centre for Human Genetics, Children's Hospital, Sheffield, England.

出版信息

Cancer Genet Cytogenet. 1988 Jul 15;33(2):213-24. doi: 10.1016/0165-4608(88)90031-3.

Abstract

The efficacy of a methotrexate (MTX) block/thymidine release synchronization technique has been assessed in bone marrow cultures from patients with acute nonlymphocytic leukemia and myelodysplasia. In contrast to cultures of stimulated lymphocytes from normal individuals, no improvement in mitotic index (MI) or metaphase quality could be detected using this technique. Demonstration of an unchanged level of division in bone marrow cultures in the presence of MTX suggests that the technique is unsuitable for synchronization purposes in this tissue. The influence of preincubation prior to MTX exposure and duration of exposure to colcemid on MI and metaphase quality have also been examined.

摘要

已对甲氨蝶呤(MTX)阻断/胸苷释放同步化技术在急性非淋巴细胞白血病和骨髓发育异常患者骨髓培养中的疗效进行了评估。与正常个体刺激淋巴细胞的培养不同,使用该技术未检测到有丝分裂指数(MI)或中期质量的改善。在存在MTX的情况下骨髓培养中分裂水平未改变,这表明该技术不适用于该组织的同步化目的。还研究了MTX暴露前预孵育以及秋水仙酰胺暴露持续时间对MI和中期质量的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验